Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

Marc A. Becker1,4*, Xiaonan Hou1, Piyawan Tienchaianada1,3, Brian B. Haines2, Sean C. Harrington1, S. John Weroha1, Sriram Sathyanarayanan2 and Paul Haluska1

Abstract

Background: Mammalian target of rapamycin (mTOR) represents a key downstream intermediate for a myriad of oncogenic receptor tyrosine kinases. In the case of the insulin-like growth factor (IGF) pathway, the mTOR complex (mTORC1) mediates IGF-1 receptor (IGF-1R)-induced estrogen receptor alpha (ERα) phosphorylation/activation and leads to increased proliferation and growth in breast cancer cells. As a result, the prevalence of mTOR inhibitors combined with hormonal therapy has increased in recent years. Conversely, activated mTORC1 provides negative feedback regulation of IGF signaling via insulin receptor substrate (IRS)-1/2 serine phosphorylation and subsequent proteasomal degradation. Thus, the IGF pathway may provide escape (e.g. de novo or acquired resistance) from mTORC1 inhibitors. It is therefore plausible that combined inhibition of mTORC1 and IGF-1R for select subsets of ER-positive breast cancer patients presents as a viable therapeutic option.

Methods: Using hormone-sensitive breast cancer cells stably transfected with the aromatase gene (MCF-7/AC-1), works presented herein describe the in vitro and in vivo antitumor efficacy of the following compounds: dalotuzumab (DALO; “MK-0646”; anti-IGF-1R antibody), ridaforolimus (RIDA; “MK-8669”; mTORC1 small molecule inhibitor) and letrozole (LET, aromatase inhibitor).

Results: With the exception of MK-0646, all single agent and combination treatment arms effectively inhibited xenograft tumor growth, albeit to varying degrees. Correlative tissue analyses revealed MK-0646 alone and in combination with LET induced insulin receptor alpha A (InsR-A) isoform upregulation (both mRNA and protein expression), thereby further supporting a triple therapy approach.

Conclusion: These data provide preclinical rationalization towards the combined triple therapy of LET plus MK-0646 plus MK-8669 as an efficacious anti-tumor strategy for ER-positive breast tumors.

Keywords: Receptor, IGF type 1, Receptor, Insulin, mTOR inhibitor, Drug resistance, Neoplasm, Breast neoplasms/drug therapy, Aromatase inhibitors/therapeutic use, Disease models, Animal

* Correspondence: becke344@gmail.com
1Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
4Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA
Full list of author information is available at the end of the article

© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The mammalian target of rapamycin (mTOR) is a master regulator of nutrient sensing (mTORC2) and growth factor signaling (mTORC1) in normal cells and its dysfunction is implicated in the malignant transformation for a variety of cancer types. As activation of mTOR can confer primary resistance to endocrine therapy, a number of prospective clinical trials (Phase II and III) have reported improved survival benefit for hormone receptor-positive breast cancer patients receiving hormone therapy in combination with an mTOR inhibition [1]. However, secondary resistance to mTOR inhibitors remains problematic as suppression of negative feedback inhibition via mTORC1 blockade can induce the IGF type-1 receptor (IGF-1R) and subsequently increase both PI3K and MAPK signaling cascades [2, 3].

The completion of three recent clinical trials, two of which specifically examined MK-0646 and MK-8669, reinforce the added value of targeting IGF-1R in conjunction with mTOR in advanced hormone receptor-positive breast cancer tumors. In a recent report, Di Cosimo and colleagues recently reported that the combination of dalotuzumab (DALO; "MK-0646"; anti-IGF-1R antibody) and ridaforolimus (RIDA; "MK-8669"; mTOR inhibitor) had evidence of antitumor activity in estrogen receptor positive (ER+)/proliferative breast cancer patients that were refractory to multiple chemotherapy regimens. Additional findings from this study suggest that more aggressive ER-positive luminal B subtype tumors exhibited high IGF signaling activation and low RAS pathway activation and that combined MK-8669/MK-0646 combination therapy may be most appropriate for this subset of patients. These data suggest that combination MK-0646 and MK-8669 may be a promising new regimen for ER-positive breast cancer patients whom may have limited benefit from hormonal therapy [4].

To determine the potential anti-tumor benefit of MK-0646 as an effective adjuvant to combination LET and/or MK-8669, xenograft studies were performed in athymic nude mice bearing tumors of hormone-sensitive breast cancer cells stably transfected with the aromatase gene (MCF-7/AC-1). Both in vitro and in vivo correlative samples were interrogated post-treatment to assess total and/or phosphorylated protein expression (e.g. AKT, S6K1, IGF-1R, MAPK, etc.) post drug administration. In addition, insulin receptor isoform expression was evaluated by qPCR for select treatment subsets. With the exception of MK-0646, all treatments were effective in suppressing tumor growth compared with controls. While MK-8669 further enhanced LET-induced growth inhibition, MK-0646 was less effective than LET alone and LET + MK-0646 was similar to LET alone, likely due to upregulation of InsR-A (confirmed by qPCR and western blot analysis). Insulin signaling through mTOR can be inhibited by the addition of MK-8669, which enhances this activity. Abrogated p70S6K1 and increased Akt phosphorylation confirmed MK-8669 target inhibition. RNAseq analysis revealed MK-0646 alone significantly downregulated IGF/Ins signaling pathway compared to the untreated control tumors and the triple therapy (LET + MK-8669 + MK-0646) significantly impaired the DNA damage repair pathway. While MK-0646 did not significantly enhance LET + MK-8669 tumor growth inhibition, the triple therapy was the most effective therapy in vivo to further support its utility in aggressive ER-positive breast cancer tumors.

Methods

Cell lines and reagents
Phenol red–free modified IMEM, DMEM, penicillin/streptomycin solution, 0.05 % trypsin-EDTA solution, Dulbecco’s PBS, and genetin (G418) were obtained from Life Technologies. Fetal bovine serum (FBS) and charcoal/dextran–treated FBS were obtained from Hyclone. Androstenedione, tamoxifen (for in vivo use), and hydroxypropyl cellulose were obtained from Sigma Chemical Co (St. Louis, MO). Matrigel was purchased from BD Biosciences. Enhanced chemiluminescence [5] kits were purchased from Amersham Biosciences. IGF-1 was purchased from GroPep. Antibodies against p-MAPK, MAPK, AKT, p-AKT, IGF-1Rβ and p-IGF-1Rβ were purchased from Cell Signaling Technology. An antibody against β-actin was purchased from Sigma-Aldrich. Horseradish peroxidase–conjugated anti-mouse and anti-rabbit secondary antibodies were purchased form Invitrogen. Antibody against insulin Rβ was purchased from Santa Cruz Biotechnology. MCF-7 human breast cancer cells stably transfected with the human aromatase gene (MCF-7/AC-1 cells) were kindly provided by Dr. Angela Brodie and Shiuian Chen (Beckman Research Institute of City of Hope, Duarte, California) as previously reported [6]. Letrozole was purchase from LKT Laboratories, Inc. (Cat# L1878, St Paul, MN, USA). Cells were routinely maintained in DMEM with 10 % fetal bovine serum, 1 % penicillin/streptomycin solution, and geneticin (G418), the culture medium changed twice weekly and origin authenticated by Genetica DNA Laboratories Inc. at the time of study.

Immunoblotting
For in vitro studies, MCF-7/AC-1 cells were cultured in IMEM steroid–reduced medium without phenol red for 24 h prior to treatment initiation with one or more of the following: vehicle control (DMSO), MK-0646 (5, 10 &15 μg/ml), MK-8669 (1, 2 & 3 μmol/L) and Letrozole under serum-free conditions. After 24 h, IGF-1 (10nM) was added to cells for 10 min. Lysates were prepared
and analyzed by immunoblot analysis as previously described [7]. Briefly, proteins were extracted from the cell culture lysate or tumor tissues by homogenization in buffer containing 50 mM Tris (pH 7.4), 1 mM EDTA, 150 mM NaCl and proteinase inhibitors (1 μg/ml phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin and 1 μg/ml leupeptin). Homogenates were centrifuged at 2000 g for 15 min at 4 °C. After centrifugation at 10,000 x g for 5 min, the supernatants were separated and their protein concentrations were measured. The supernatants were separated by 10 % SDS-PAGE, transferred onto Immuno-Blot polyvinylidene difluoride (PVDF) membrane (catalog no. 162–0177, Bio-Rad), and Western blot analysis was performed. Membranes were blocked with 5 % milk in TBS (10 mM Tris–HCl (pH 8.0) and 150 mM NaCl) plus 0.05 % Tween-20 overnight at 4 °C prior to primary (24 h) and subsequent secondary (1 h) antibody exposure. Proteins of interest were detected using an ECL kit (Amersham, Arlington Heights, IL).

Clonogenics
Colony-forming assays were used to assess drug effect on cell proliferation. In short, 500 cells obtained after trypsinizing subconfluent cell culture stocks of MCF-7/AC-1 were seeded in 35 mm tissue culture plates (in triplicate) and allowed to adhere overnight. The plated cells were treated with DMSO/diluent (0.1 %) or MK-0646, MK-8669 or MK-0646 plus MK-8669 at the indicated concentrations under serum-free conditions. MCF-7/AC-1 cells were treated with IGF-1 100 nanogram/ml during drug exposure. Following three days of treatment, plates were washed with PBS and media replaced with DMEM (10 % fetal bovine serum, 1 % penicillin/streptomycin solution. The plated cells were allowed to proliferate to form colonies for 7 days. Then plates were washed with PBS, stained with Coomassie blue, and colonies counted on the G:BOX imager system using GeneTools software (Syngene). Results were evaluated graphically using GraphPad PRISM software. Each presented figure is a representative of one of at least three independent experiments, each performed in triplicate. The method of Chou and Talalay was used to determine synergy as described previously [8]. Median effect analysis was done using Calcusyn software (BioSoft). With this method, a combination index (CI) > 1 is deemed antagonistic, a combination index < 1 is synergistic, and combination index = 1 is considered additive. Surface response contours and modeling were carried out in MATLAB as previously described [9].

Xenograft studies
Female ovariectomized BALB/c athymic nude mice 4–6 weeks of age were obtained from Harlan Laboratories (Indianapolis, IN) and housed in a pathogen-free environment. All animal studies and experiments described herein were carried out and approved according to the guidelines of the Mayo Clinic Institutional Animal Care and Use Committee. Animals were allowed to acclimatize for ≥ 48 h prior to tumor implantation. MCF-7/AC-1 cells were cultured to sub-confluence and suspended in Matrigel (10 mg/mL) at a concentration of 2.5 x 10^7 cells/mL for subcutaneous flank injection (100μL). Mice were randomized to their respective treatment groups using JMP (SAS, Cary, NC) as tumors reached the appropriate size (~250 mm^3). Tumors were measured weekly with calipers, and volumes calculated according to the following formula: \( \Delta V = \frac{4}{3} \pi r_1^3 - \frac{4}{3} \pi r_2^3 \) (where \( r_1 < r_2 \)), where \( r \) is the smaller radius. The nonsteroidal aromatase inhibitor Letrozole (10ug/day) and antiestrogen tamoxifen (500 μg/day) were prepared as suspensions (0.3 % hydroxypropyl cellulose) and administered subcutaneously (daily) for 28 days. Dalotuzumab (DALO; “MK-0646”: anti-IGF-1R antibody) was administered weekly via IP injection at a dose of 20 mg/kg for a total of 4 weeks. Ridaforolimus (RIDA; “MK-8669”; mTOR inhibitor) was administered IP at a dose of 1 mg/kg for five continuous days (Qdx5) for total 4 weeks. All groups were subcutaneously supplemented with daily androstenedione (100 μg) for the experimental duration as previously described [10]. Mice were monitored daily and weighed once per week. Tumor volume change was calculated when the treatment period was finished, TVC = \( \Delta V / V_{treatment} \) x 100, where DT stands for mean tumor volume change of each treatment group and AC for mean tumor volume change of control group. Tumor volume and body weight data were analyzed by one-way ANOVA test (GraphPad). At the time of euthanasia, tumors were rapidly excised, weighed and preserved for downstream correlative analyses as snap-frozen and in RNA Later (Invitrogen Life Technologies, Carlsbad, CA, USA).

Quantitative PCR
Total RNA was isolated using Trizol reagents (Cat#15596-026, Invitrogen, Carlsbad, CA). DNA was reverse transcribed using ABI High capacity RNA to cDNA kit (Applied Biosystem, Carlsbad, CA) as per the manufacturer’s instructions. Sample RNA quality was assessed within each group post reverse-transcriptionally through ribosomal protein 19 (RPL19) expressions. Normalization ratios for each sample were calculated (Nsample = RPL19median/RPL19sample) and compared to the group mean. Samples with RPL19 normalization ratios greater than +3.5 standard deviations (SD) (approximately 99.9 % confidence interval) from the mean were excluded from further analysis. The standard replicates for each qPCR assay were examined for amplification efficiencies between 95–105 % and all standards
and sample replicate data were analyzed for product specific melt cures. Sample or standard replicates which did not conform to these parameters were removed from the analysis. Gene transcript copy numbers from each conforming replicate were normalized to RNA input and RPL19 gene expression before being reported as copies of target gene per μg RNA as previously described [11].

RNA-seq
MCF-7/AC-1 xenograft tumor RNA integrity was confirmed using the Agilent 2100 Bioanalyser (Agilent Technologies, USA) and next-generation sequencing was performed at Merck Co using the Illumina Hiseq 2000 platform (paired-end sequencing, 100 base pairs). RNA-seq data was analyzed with Partek Flow as previously described. Briefly, reads were mapped to the human genome (Ensembl GRCh37) and quantified using the STAR aligner, aligned reads to genes using Partek E/M and differentially expressed genes determined using gene-specific analysis (GSA).

Results
IGF-1R inhibition (MK-0646) does not enhance hormonal therapy (letrozole or tamoxifen) in MCF-7/AC-1 xenografts
Based on our previous investigations demonstrating enhanced activity of hormonal therapy in combination with IGF inhibition, the in vivo anti-tumor potential of MK-0646 plus letrozole (LET) or tamoxifen (TAM) was determined [10] (Fig. 1). MCF-7/AC-1 xenografts were established and as tumors reached the appropriate size (250 mm³) mice were randomized to one of the following treatment cohorts (n ≥ 4 mice/cohort) for a duration of 28 days: Control (vehicle alone), TAM, LET, MK-0646, TAM + MK-0646, LET + MK-0646. Hormonal therapy alone significantly inhibited tumor growth as compared to control and LET was superior to TAM in terms of percent inhibition (34.6 vs. 28.6 %) and statistical significance (P < 0.001 vs. P < 0.05). While MK-0646 alone did not significantly inhibit tumor growth, the combination LET + MK-0646 was more effective than combination TAM + MK-0646 (41.7 vs. 30.9 %) and resulted in the greatest degree of tumor growth inhibition. Of note, all treatments were well tolerated as bodyweight was maintained throughout study duration (data not shown).

MK-0646 increases Insulin Receptor A Isoform expression in MCF-7/AC-1 xenografts
In contrast to a small molecule inhibitor targeting IGF-1R and insulin receptor (IR), MK-0646 failed to improve anti-tumor response to hormonal therapy in ER-positive breast cancer xenografts (Fig. 1). To delineate potential compensatory mechanisms, post-treatment tumors were assessed for IGF1R and IR isoform gene expression (Fig. 2). MK-0646 significantly increased both IGF1R and IR isoform gene expression, IRB to a lesser extent as compared to IRA (Fig. 2a). While the addition of hormonal therapy had little impact, overall IRA expression was highest in LET + MK-0646 tumors (Fig. 2a). MK-0646 induces receptor internalization, leading to subsequent degradation and a reduction in IGF-1R protein levels. Treatments with LET and/or MK-0646, as in Fig. 1, were repeated, but were also terminated at days 7 and 14 days to investigate potential temporal modulations in receptor expression (Fig. 2b). Regardless of time point, IGF-1R expression was markedly reduced in all MK-0646 treatment cohorts. While MK-0646 alone decreased IR expression, the combination LET + MK-0646, following an initial decline at Days 7 and 14, resulted in the highest level of IR expression at Day 28. Statistical analyses for IGF1R, IRA and IRB are included (Additional file 1: Table S1; Additional file 2: Table S2; Additional file 3: Table S3).

Persistent mTOR signaling in response to IGF-1R inhibition is overcome by MK-8669
Based on the aforementioned finding where MK-0646 upregulated IRA levels, potential compensatory mechanisms (e.g. IR signaling via mTOR) resulting from IGF-1R/ER-targeted inhibition were examined (Fig. 3). Prior to IGF-induced IGF-1R activation, serum-starved MCF-7/AC-1 cells were incubated for 24 h with LET and/or increasing concentrations of MK-0646 and/or MK-8669 (Fig. 3a). As expected, IGF-1 ligand resulted in robust IGF-1R phosphorylation in MCF-7/AC-1 cells. MK-
MK-0646 and MK-8669 synergistically inhibit clonogenesis

Based on the above findings, the synergistic potential of combined mTOR/IGF-1R inhibition was examined (Fig. 4). Specifically, colony formation in response to increasing doses of MK-0646, MK-8669 or the combination MK-0646 + MK-8669 was determined in MCF-7/AC-1 and MCF-7/AC-1/IGF-2 cells (Fig. 4a). MK-0646 alone elicited little (MCF-7/AC-1) to no effect (MCF-7/AC-1/IGF-2). Conversely, MCF-7/AC-1/IGF-2 cells were more sensitive to MK-8669 (IC50 = 5.9nM vs. 27.2nM). While the combination resulted in synergy across cell lines, the magnitude of synergy varied as combination index (CI) values were superior in MCF-7/AC-1 vs. MCF-7/AC-1/IGF-2 cells (e.g. 0.062 vs. 0.251). Surface response modeling was employed to illustrate the synergistic potential of MK-0646 + MK-8669 in MCF-7/AC-1 cells (Fig. 4b). These data support multiplicative benefit of adding MK-0646 to existing MK-8669 in ER-positive breast cancer cells and further implicate the IGF-2/IR-A signaling axis as a potential resistance pathway. The remaining works presented herein center upon elucidating the in vivo impact and correlative molecular repercussions of said targeted therapies in parental MCF-7/AC-1 xenografts.

MK-0646 and MK-8669 synergistically inhibit clonogenesis

Based on the above findings, the synergistic potential of combined mTOR/IGF-1R inhibition was examined (Fig. 4). Specifically, colony formation in response to increasing doses of MK-0646, MK-8669 or the combination MK-0646 + MK-8669 was determined in MCF-7/AC-1 and MCF-7/AC-1/IGF-2 cells (Fig. 4a). MK-0646 alone elicited little (MCF-7/AC-1) to no effect (MCF-7/AC-1/IGF-2). Conversely, MCF-7/AC-1/IGF-2 cells were more sensitive to MK-8669 (IC50 = 5.9nM vs. 27.2nM). While the combination resulted in synergy across cell lines, the magnitude of synergy varied as combination index (CI) values were superior in MCF-7/AC-1 vs. MCF-7/AC-1/IGF-2 cells (e.g. 0.062 vs. 0.251). Surface response modeling was employed to illustrate the synergistic potential of MK-0646 + MK-8669 in MCF-7/AC-1 cells (Fig. 4b). These data support multiplicative benefit of adding MK-0646 to existing MK-8669 in ER-positive breast cancer cells and further implicate the IGF-2/IR-A signaling axis as a potential resistance pathway. The remaining works presented herein center upon elucidating the in vivo impact and correlative molecular repercussions of said targeted therapies in parental MCF-7/AC-1 xenografts.

In vivo activity of LET +/- MK-0646 +/- MK-0646 in MCF-7/AC-1 xenografts

To determine if the described in vitro MK-0646 + MK-8669 synergy translated in vivo, established MCF-7/AC-1 xenografts were allowed to reach the appropriate size (250 mm3) and mice randomized to one of the following 28-day treatment cohorts (n ≥ 7 mice/ cohort): Control, LET, MK-8669, MK-0646, MK-8669 + MK-0646, LET +
MK-0646, LET + MK-8669 or LET + MK-0646 + MK-8669. While the impact of MK-0646 on tumor growth remained negligible, single agent MK-8669 and LET led to significant tumor regression compared to untreated control (Fig. 5a). Although not significant compared to LET + MK-8669, the triple combination LET + MK-8669 + MK-0646 led to the largest numerical regression compared to untreated control tumors (62.7 % reduction). Statistical analyses comparing treatment cohorts are included (Additional file 4: Table S4). In addition, all agents (both alone and in combination) were well tolerated, as bodyweight did not significantly differ across cohorts throughout treatment duration (data not shown).

To investigate the biochemical effect(s) of the aforementioned therapies, post treatment tumors were harvested at treatment end (Day 28) and subjected to western blotting (Fig. 5b). As demonstrated in vitro, single agent efficacy was confirmed as MK-0646 down-regulated IGF-1R and MK-8669 resulted in both decreased S6K1 phosphorylation and, albeit to a lesser extent, increased Akt phosphorylation. In addition, MK-8669 led to increased IGF-1R/IR phosphorylation and MK-8669 + MK-0646 further enhanced levels, the result(s) of which may be attributable to IR compensation. Compared to LET + MK-8669, the triple combination LET + MK-8669 + MK-0646 was most effective in terms of decreased total IGF-1R and phosphorylated IGF-1R/IR, Akt, S6K1 and MAPK. These data support co-targeting IGF-1R and mTOR in ER-responsive breast cancer.

RNA-seq analysis reveals both overlapping and distinct gene regulation in MCF-7/AC-1 xenografts

To better understand the transcriptional impact and potential changes in the molecular landscape resulting from targeted IGF-1R, mTOR and ER inhibition, an unbiased, comprehensive analysis of post-treatment tumors by RNA-seq was performed (Fig. 6). A complete list of all treatment-induced gene expression changes according to directional magnitude are included (Additional file 5: Table S5). As opposed to in vivo tumor repression, where single agent LET and MK-8669 were significantly better than MK-0646, ER (51 genes) and mTOR (160 genes) inhibition altered few genes compared to IGF blockade (1,163 genes). However, when combined with
one another, major increases were observed (e.g., 1,711 genes in LET + MK-8669). In an effort to better understand gene expression changes across cohorts, treatments were normalized to controls and presented as a multi-set Venn diagram (Fig. 6a). Depending on the contrast, overlapping (e.g., LET + MK-8669 vs. LET + MK-8669 + MK-0646) or distinct (e.g., LET + MK-8669 vs. LET + MK-8669 + MK-0646) gene expression patterns...
were observed. A heatmap depicting the most significantly regulated genes in the LET + MK-8669 + MK-0646 cohort illustrate the co-regulatory nature (both direction and magnitude) with LET + MK-8669 (Fig. 6b). Upon close examination, the majority of downregulated genes have been linked to a more aggressive breast tumor phenotype. However, numerous upregulated genes have associated with breast tumor progression and metastasis, suggesting possible compensatory transcriptional alterations to overcome treatment-induced anti-tumor effects.

Functional analysis was performed in IPA (Ingenuity Pathway Analysis) was performed to assess global transcription (Additional file 6: Table S6). Although MK-0646 was the only treatment that failed to inhibit in vivo tumor growth, antibody efficacy was first confirmed as 'IGF-1 Signaling' was predicted as a significantly inhibited pathway in the MK-0646 cohort. Using p-value and z-score, the 'The Role of BRCA1 in DNA Damage Response' was predicted as the top canonical pathway across treatments (Additional file 7: Figure S1). A heatmap of pathway-specific genes within each treatment confirmed that DNA damage response was most impaired in the LET+ MK-8669 + MK-0646 cohort (Additional file 8: Figure S2). Therefore, combined ER/mTOR/IGF targeting may greatly sensitize tumors to DNA-damaging agents (e.g. standard chemotherapy) and as a result, efforts to test the triple therapy with standard of care chemotherapies are being explored.

Discussion
A plethora of preclinical data supports targeted inhibition of the IGF pathway across numerous cancer types [12]. Unfortunately, a general lack of activity is a common stigmata of IGF-1R inhibitors in breast cancer [13]. To highlight this point, a randomized, controlled, double-blind, phase 2 trial examining the potential benefit of adding the IGF-1R inhibitor ganitumab (AMG 479) to hormonal therapy in patients with hormone-receptor positive breast cancer reported negative results [14]. The failure of ganitumab and other IGF-targeting agents has been widely attributed to poor patient selection (e.g. lack of predictive biomarkers) and/or unforeseen compensatory signaling networks (e.g. HER, IR, IGFBPs) [15–18]. As a result, additional studies to identify, and potentially target, the key factors mediating anti-IGF-1R resistance are of high interest in the field of oncology.

Targeting of the IGF-1R promotes receptor tyrosine kinase cross-talk and leads to the subsequent compensatory activation of a myriad of downstream signaling molecules known to play a role in resistance and tumorogenic behavior(s). IR represents the closest relative to IGF-1R and is linked to anti-IGF-1R monoclonal antibody resistance via heterodimer formation (IGF-1R:IR) and/or IGF-2/IRA signaling as IRA is commonly present in a variety of solid tumors [19–21]. The fetal or A form of the IR appears to have a more mitogenic role in cancer cell proliferation than its purely metabolic isoform IRB [22]. The varying biological activities of IR isoforms likely relate to their differing affinities towards IGF ligands. Specifically, the metabolic IRB binds only insulin at physiologic concentrations, whereas the mitogenic IRA is able to bind and be activated by IGF-2 [23]. Thus, IRA through dimerization with IGF-1R (IGF-1R:IR) or homo-dimerization may provide mitogenic activities to cancer cells via IGF-2 activation. Accumulated data has implicated IRA, or the IR total content, as an important factor in breast cancer outcome and implicates IRA as a mechanism of resistance towards DNA-damaging agents (e.g. standard chemotherapy) and as a result, efforts to test the triple therapy with standard of care chemotherapies are being explored.
therapies specifically targeting IGF-1R, namely monoclonal antibody therapeutics. Patients with node negative breast cancers whose tumors express high IR, compared to even moderate IR content, report poor disease-free survival intervals [24]. Early studies have also shown that roughly 80% of breast cancers have an IR content higher than the median content found in the normal breast and approximately 20% of cancers present 10-fold higher levels of IR levels than the median value of normal breast tissue. Early studies targeting IGF-1R receptor in patients with refractory tumors have demonstrated that monoclonal antibody therapies may induce upregulation of insulin secretion, thereby implicating it as a compensatory mechanism that could possibly activate IR signaling as a mechanism of resistance [25].

While epithelial breast cancer cells commonly overexpress IGF-1R, surrounding tumor-associated stroma provides a rich source of IGF-2 [26]. Upon binding to IGF-2, both IR-A and IGF-1RIR hybrid receptors are thought to promote proliferative and tumorigenic behavior predominantly via MAPK and PI3K/Akt signaling, both of which converge upon the mTOR/S6K1 axis as a critical mediator of cell growth, survival and metabolism [27]. Negative feedback inhibition of the IGF pathway via canonically active mTOR/S6K1 effectively limits IGF-1R signaling. As a result, mTOR inhibitors alleviate IGF-1R repression and increase Akt activation as a potential mechanism of resistance [3]. Moreover, a dynamic interplay between IGF and ERα in breast cancer cells has been demonstrated, where IGF-1R increase

Fig. 6 RNaseq analysis reveals both overlapping and non-overlapping gene expression patterns in MCF-7/AC-1 xenografts. a Venn Diagram of the overlapping and unique number of genes according to treatment cohort(s). b Heatmap depicting the most significantly up (red) and down (green) regulated genes in LET + MK-8669 + MK-0646-treated tumors compared to the remaining treatment cohorts. Color bar indicates log-fold expression change compared to control tumors.
ERα phosphorylation and activity via mTOR/S6K1 and ERα mediates IGF-1R, IRS-1 and IGF ligand expression [28]. Thus, combined IGF-1R/mTOR inhibition plus hormone therapy in breast cancer cells presents as a viable therapeutic option.

**Conclusions**

Data herein demonstrate that, similar to clinical trials, IGF-1R inhibition (via MK-0646) does not enhance hormonal therapy in ER-positive breast cancer cells, the results of which may be attributable to compensatory IGF-2/IRA activity. Although IRA-induced signaling remains a potential confounder as a potential escape pathway, biochemical and in vivo studies support combined IGF/mTOR/ER inhibition. Importantly, for the first time, synergistic inhibition is demonstrated when combining IGF-1R and mTOR targeting agents in breast cancer cells. Finally, combined IGF/mTOR/ER inhibition was most effective in limiting tumor growth and markedly altered transcriptional activity in ER-positive breast cancer tumors.

**Additional files**

- Additional file 1: Table S1. Statistical analysis of IGF1R expression for samples depicted in Fig. 1. (XLSX 44 kb)
- Additional file 2: Table S2. Statistical analysis of IRA expression for samples depicted in Fig. 1. (XLSX 44 kb)
- Additional file 3: Table S3. Statistical analysis of IRB expression for samples depicted in Fig. 1. (XLSX 44 kb)
- Additional file 4: Table S4. Statistical analysis of final tumor volume for samples depicted in Fig. 5. (XLSX 44 kb)
- Additional file 5: Table S5. Gene expression values for all treatment cohorts expressed as relative fold-change compared to control. (XLSX 623 kb)
- Additional file 6: Table S6. Ingenuity Pathway Analysis. (XLSX 115 kb)
- Additional file 7: Figure S1. Pathway inhibition of the Role of BRCA1 in DNA Damage Response in LET + MK-8669 + MK-0646 tumors. Highlighted in green are the significantly downregulated genes compared to control tumors. (PDF 415 kb)
- Additional file 8: Figure S2. Heatmap depicting DNA damage gene expression across treatment cohorts. Color bar indicates log-fold expression change compared to control tumors. (PDF 92 kb)

**Abbreviations**

DALO: Dalotuzumab; ERα: Estrogen receptor alpha; IGF: Insulin-like growth factor; IGF-1R: IGF-1 receptor; InsR-A: Insulin receptor alpha A; IRS: Insulin receptor substrate; LET: Letrozole; MTOR: Mammalian target of rapamycin; mTORC1: mTOR complex; RIDA: Ridaforolimus

**Acknowledgements**

Not applicable.

**Funding**

Supported in part by the Mayo Clinic Breast SPORE (CA116201-03), National Institutes of Health Endocrine Training Grant T32 DK07352 and Merck Co.

**Availability of data and materials**

RNA-seq data generated from xenograft breast cancer tumors were submitted to Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with accession number: GSE79492 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79492).

**Authors’ contributions**

MAB, XH, BBH, SS, SJW and PH participated in the conception and design of the study and the development of methodology. XH, PT and SCH performed the experiments and acquired the data. MAB, XH, SJW and PH were involved in the analysis and interpretation. MAB and BBH performed the bioinformatics and biostatistics analyses. MAB, XH and PH contributed significantly to the writing, review and/or revision of the manuscript. All authors provided critical comments of the manuscript and have read and approved the final version of the manuscript.

**Competing interests**

BBH and PH are employees of Merck & Co. SS is an employee of Jounce Therapeutics, Inc. No non-financial conflicts of interest exist for any of the authors.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Author details**

1Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.

2Molecular Oncology, Merck Research Laboratories, Boston, MA 02115, USA.

3Oncology unit, Department of Medicine, Rajavithi Hospital, Bangkok 10440, Thailand.

4Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55902, USA.

**Received**: 29 June 2015 **Accepted**: 7 October 2016

**Published online**: 20 October 2016

**References**

1. Vicier C, Dieci MV, Amedos M, Delaloge S, Wiens P, Andre F. Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Res. 2014;16:203.

2. Caracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a P38-dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065–74.

3. O’Reilly KE, Rojo F, She QB, Solt D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res. 2006;66:1500–8.

4. Di Cosimo S, Sathyarayanan S, Bendell JC, Cervantes A, Stein MN, Brana I, et al. Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clin Cancer Res. 2015;21:49–59.

5. Timmermans F, Velghe I, Vanvalleghem L, De Smedt M, Van Coppenolle S, Taghon T, et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol. 2009;182:6879–88.

6. Zhou DJ, Popon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 1990;50:6949–54.

7. Hou X, Tan Y, Li M, Dey SK, Das SK. Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrinol. 2004;18:3035–49.

8. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–57.

9. Kern SE, Xie G, White JL, Egan TD. A response surface analysis of propofol-remifentanil pharmacodynamic interaction in volunteers. Anesthesiology. 2004;100:1373–81.

10. Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Geer A, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011;71:7597–607.

11. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res. 2012;22:108–15.

12. Pollak M. Targeting insulin and insulin-like growth factor signalling in breast cancer. Breast Cancer Res. 2014;16:203.

13. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst. 2012;104:975–81.

14. Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced breast cancer who have progressed on previous endocrine therapy (HERGON): a phase 3, randomised, placebo-controlled, double-blind, multicentre trial. Lancet Oncol. 2013;14:1103–13.
with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013;14:228–35.
15. Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, et al. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Breast Cancer Res. 2012;18:1808–17.
16. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther. 2008;7:2589–98.
17. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res. 2012;72:3372–80.
18. King H, Alekis C, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 2014;40:1096–105.
19. Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, et al. Heterodimerization of glycosylated insulin-like growth factor-I receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One. 2012;7:e33322.
20. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A. 2010;107:10791–8.
21. Bid HK, Zhan J, Phelps DA, Krumasheva RT, Houghton PJ. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther. 2012;11:549–59.
22. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene. 1999;18:2471–9.
23. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneti R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 2002;277:39684–95.
24. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneti R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians. 1997;109:565–71.
25. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Breast Cancer Res. 2007;13:5834–40.
26. Ellis MJ, singer C, Hornby A, Rasmussen A, Cullen KJ. Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer. Breast Cancer Res Treat. 1994;31:249–61.
27. Malaguarnera R, Belfiore A. The insulin receptor: a new target for cancer therapy. Front Endocrinol. 2011;2:293.
28. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol. 2011;25:516–28.